These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Regulation of protein kinase C-delta and -epsilon isoforms by phorbol ester treatment of LLC-PK1 renal epithelia.
    Author: Clarke H, Ginanni N, Soler AP, Mullin JM.
    Journal: Kidney Int; 2000 Sep; 58(3):1004-15. PubMed ID: 10972665.
    Abstract:
    BACKGROUND: LLC-PK1 renal epithelia are a widely used model for proximal tubular physiology and differentiation. Protein kinase C (PKC) has been observed to play a role in both processes. This study examines the subcellular distribution and down-regulation of PKC-delta and PKC-epsilon isoforms in phorbol ester-treated LLC-PK1 epithelia. METHODS: Cells were treated with 10-7 mol/L 12-O-tetradecanoyl phorbol 13-acetate (TPA) for up to seven days and were extracted as total cell lysates as well as cytosolic, membrane-associated (Triton-X soluble) and a third (Triton-X insoluble) fraction. The expression and cellular localization of PKC-delta and PKC-epsilon isoforms were then detected using Western immunoblot and immunofluorescence. RESULTS: Based on the use of an anti-PKC-delta monoclonal antibody, TPA was observed to cause a rapid decrease in total PKC-delta content, which then returned to near control levels by seven days of treatment. Immunofluorescence indicated that PKC-delta had a cytoskeletal localization within the cells, and a subtle cytoskeletal rearrangement occurred upon exposure to TPA. Western immunoblots showed that PKC-delta did not undergo the expected membrane translocation upon activation by TPA, but simply disappeared immediately from the cytosolic compartment. Conventional cell fractionation procedures such as homogenization and Triton extraction prior to Western immunoblot will, however, fail to evaluate completely PKC-delta in LLC-PK1 epithelia because of the highly stringent measures necessary to extract PKC-delta from the cytoskeletal compartment of these cells. Furthermore, we observed that a second (polyclonal) PKC-delta antibody may recognize phosphorylated forms of PKC-delta, which went unrecognized by the other antibody. PKC-epsilon was present in the cytosol, membrane, and Triton-X-insoluble fractions of the cells. TPA treatment resulted in a partial translocation of PKC-epsilon to both the membrane and Triton-X-insoluble fractions of the cell, but total PKC-epsilon remained essentially unchanged. CONCLUSIONS: The present data indicate that the localization of PKC-delta and subsequent redistribution within the LLC-PK1 cells in response to TPA treatment is highly unique and distinct from that of PKC-epsilon and PKC-alpha. An important methodological finding is that one given antibody may not recognize all phosphoproteins of a given PKC isoform.
    [Abstract] [Full Text] [Related] [New Search]